KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Payables (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Payables data on record, last reported at $14.3 million in Q3 2025.

  • For Q3 2025, Payables rose 58.26% year-over-year to $14.3 million; the TTM value through Sep 2025 reached $14.3 million, up 58.26%, while the annual FY2024 figure was $43.0 million, 65.07% up from the prior year.
  • Payables reached $14.3 million in Q3 2025 per IONS's latest filing, down from $22.8 million in the prior quarter.
  • Across five years, Payables topped out at $43.0 million in Q4 2024 and bottomed at $5.6 million in Q3 2023.
  • Average Payables over 5 years is $16.0 million, with a median of $14.3 million recorded in 2025.
  • Peak YoY movement for Payables: plummeted 72.67% in 2023, then soared 146.67% in 2025.
  • A 5-year view of Payables shows it stood at $11.9 million in 2021, then skyrocketed by 50.55% to $17.9 million in 2022, then surged by 45.23% to $26.0 million in 2023, then soared by 65.07% to $43.0 million in 2024, then crashed by 66.66% to $14.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $14.3 million in Q3 2025, $22.8 million in Q2 2025, and $17.5 million in Q1 2025.